Illumina (NASDAQ: ILMN) reported Q2 EPS of $0.62, $0.05 worse than the analyst estimate of $0.67. Revenue for the quarter fell 25% to $633 million versus the consensus estimate of $679.56 million.

“As expected, the second quarter was significantly impacted by pandemic-related disruption in our customers’ operations and was particularly challenging for many of our research customers who remain closed or operating at limited scale,” said Francis deSouza, President and CEO. “It is clear that the role of genomics in infectious disease will continue to grow through and beyond this pandemic.”

GUIDANCE:

As previously announced, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic.

For earnings history and earnings-related data on Illumina (ILMN) click here.